

Breast cancer prognosis associated with oncometabolite accumulation

December 9 2013

The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the *Journal of Clinical Investigation* Stefan Ambs and colleagues at the National Cancer Institute discovered an association between the oncometabolite 2-hydroxyglutarate (2-HG) levels, DNA methylation patterns, and breast cancer prognosis.

The authors identified a breast cancer subtype with high levels of 2-HG, and a district DNA methylation pattern that was associated with reduced survival.

This breast cancer subtype was common in African-American breast cancer patients, who as a group have a high prevalence of aggressive breast cancers.

This study indicates that evaluation of 2-HG along with DNA methylation may be a useful biomarker for <u>breast cancer</u> diagnosis and prognosis

More information: MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis, *J Clin Invest*. <u>DOI:</u> <u>10.1172/JCI71180</u>

Provided by Journal of Clinical Investigation



Citation: Breast cancer prognosis associated with oncometabolite accumulation (2013, December 9) retrieved 4 May 2024 from https://medicalxpress.com/news/2013-12-breast-cancer-prognosis-oncometabolite-

accumulation.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.